9
Participants
Start Date
November 30, 2004
Primary Completion Date
May 31, 2007
Study Completion Date
May 31, 2007
plerixafor
Participants were given a 240 µg/kg dose of plerixafor by subcutaneous injection in the morning followed by apheresis 6 hours later. Daily treatment with plerixafor followed by apheresis was administered for up to 4 consecutive days or until 4\*10\^6 CD34+ cells/kg body weight had been collected.
Memorial Sloan-Kettering Cancer Center, New York
Thomas Jefferson University, Philadelphia
Collaborators (1)
AnorMED
INDUSTRY
Genzyme, a Sanofi Company
INDUSTRY